Table 1

Clinical characteristics at 16 years follow-up

No-touch groupConventional group
Randomised patients at start of study (n)5252
Mortality after 16 years follow-up, n (%)13 (25)14 (27)
Loss to follow-up (n)21
Patients at 16 years follow-up (n)3737
Characteristics for patients at 16 years
 Age, mean±SD74.7±5.572.9±7.2
 Male, n (%)35 (94.6)30 (81.1)
Risk factors
Family history, n (%)21 (56.8)26 (70.3)
Previous AMI, n (%)20 (54.1)20 (54.1)
Smokers, n (%)4 (10.8)5 (13.5)
Diabetes, n (%)11 (29.7)9 (24.3)
Hyperlipidaemia, n (%)36 (97.3)33 (89.2)
Hypertension, n (%)19 (51.4)20 (54.1)
Blood chemistry:
S-cholesterol (mmol/L), mean±SD4.7±1.04.7±1.1
S-LDL (mmol/L), mean±SD2.5±0.82.7±1.1
S-HDL (mmol/L), mean±SD1.2±0.31.1±0.2
S-Triglycerides (mmol/L), mean±SD2.1±1.01.8±0.9
β-glucose >6.1 mmol/L, n (%)20/34 (58.8%)13/31 (41.9%)
BNP ≥150 ng/L, n (%)10/33 (30.3%)11/29 (37.9%)
Blood pressure (>140/90 mm  Hg), n (%)11 (29.7)8 (21.6)
Medical treatment
β-blockers, n (%)28 (75.7)29 (78.4)
Ca-inhibitor, n (%)10 (27)8 (21.6)
ASA, n (%)35 (94.6)34 (91.9)
Statins, n (%)35 (94.6)32 (86.5)
Nitrates, n (%)5 (13.5)8 (21.6)
Diuretics, n (%)8 (21.6)7 (18.9)
ACE-inhibitor or AII blockade n (%)16 (43.2)22 (59.5)
Peroral diabetic medication, n (%)4 (10.8)3 (8.1)
Insulin diabetic medication, n (%)3 (8.1)0 (0)
Both peroral and insulin, n (%)4 (10.8)6 (16.2)
  • There were no statistically significant differences between the groups

  • ASA, acetyl salicylic acid; AMI, acute myocardial infarction; BNP, brain natriuretic peptide; S-HDL, serum high-density lipoprotein; S-LDL, serum low-density lipoprotein.